<DOC>
	<DOCNO>NCT00743925</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy A 002 added high dose atorvastatin subject acute coronary syndrome ( ACS )</brief_summary>
	<brief_title>FRANCIS-ACS Trial : A Study Safety Efficacy A 002 Subjects With Acute Coronary Syndromes</brief_title>
	<detailed_description>This double-blind randomized parallel group placebo control study subject present ACS . Subjects randomize receive either A 002 500 mg daily ( QD ) placebo tablet addition 80 mg atorvastatin QD . Randomization must occur within ≤96 hour hospital admission index ACS event , , already hospitalize , within ≤96 hour index event diagnosis . Follow-up visit occur Weeks 2 , 4 , 8 , 12 , 16 , 20 , 24 post-randomization ; monthly thereafter study completion . All enrolled subject remain treatment subject treat minimum 24 week occurrence Major Adverse Cardiac Event ( MACE ) . At point , active subject ( early withdrawn already MACE ) bring Final Study Visit . Subjects complete Final Study Visit may eligible enroll open-label extension study 2 year total study drug exposure .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Varespladib methyl</mesh_term>
	<criteria>Men woman ≥18 year age A diagnosis unstable angina , NSTEMI , STEMI Any one follow criterion : Diabetes , CRP ≥2 mg/L , metabolic syndrome Subjects must randomize within 96 hour index event Percutaneous revascularization , require plan , must occur prior randomization Subjects must NOT meet follow exclusion criterion : Subjects enrol another experimental ( interventional ) protocol within past 30 day prior Screening . Subjects treat cancer within previous 5 year except skin basal cell carcinoma carcinoma situ cervix , measure minor , complete surgical excision ( e.g. , chemotherapy ) , radiation therapy . The presence severe liver disease cirrhosis , recent active hepatitis , active chronic hepatitis , ALT AST &gt; 3 x ULN , biliary obstruction hyperbilirubinemia ( total bilirubin &gt; 2 x ULN ) Active cholecystitis , gall bladder symptom , potential hepatobiliary abnormality The presence severe renal impairment ( CrCl &lt; 30 mL/min creatinine &gt; 3 x ULN ) , nephrotic syndrome , patient undergoing dialysis Uncontrolled diabetes mellitus ( HbA1c &gt; 11 % within last 1 month prior Screening ) Females nursing , pregnant , intend become pregnant time study , female childbearing potential positive pregnancy test screen evaluation . Women childbearing potential must also use reliable method birth control study 1 month follow completion therapy . A reliable method study define one following : oral injectable contraceptive , IUD , contraceptive implant , tubal ligation , hysterectomy , barrier method ( diaphragm spermicidal foam jelly , condom ) . Subjects history alcohol drug abuse within 1 year study entry Subjects live far participate center unable return followup visit Subjects opinion Investigator poor medical psychiatric risk therapy investigational drug , unreliable , incomplete understand study may affect ability take drug prescribe comply instruction Known HIV , Hepatitis B C virus , tuberculosis infection Acute bacterial , fungal viral infection Any current statin therapy maximum recommend dosage . For atorvastatin , fluvastatin , lovastatin , pravastatin simvastatin 80 mg QD time index event rosuvastatin 20 mg QD 40 mg QD Drugs potent inhibitor cytochrome P450 unless withdrawn Subjects NYHA Class III IV heart failure , LVEF &lt; 30 Subjects moderate severe aortic stenosis , aortic regurgitation , mitral stenosis mitral regurgitation Ventricular arrhythmia require chronic drug treatment ICD Subjects stenosis stenosis &lt; 50 % angiography Subjects pacemaker persistent LBBB LDLC &gt; 200 mg/dL ( 5.2 mmol/L ) Fasting triglyceride level ≥400 mg/dL ( 4.5 mmol/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Unstable Angina</keyword>
	<keyword>STEMI</keyword>
	<keyword>NSTEMI</keyword>
	<keyword>ACS</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>C14.280.647.124</keyword>
	<keyword>C14.280.647.500</keyword>
</DOC>